Targeting Epigenetic Modifiers for Cancer Treatments

[1]  Wenjie Miao,et al.  EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma , 2018, Molecular and Cellular Biochemistry.

[2]  Yanping Ma,et al.  Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[3]  S. Narayanan,et al.  Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts , 2017, Anti-cancer drugs.

[4]  I. Feldman,et al.  EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL , 2017, Molecular Cancer Therapeutics.

[5]  Longchang Huang,et al.  EZH2 is involved in silencing of WNT5A during epithelial–mesenchymal transition of colon cancer cell line , 2017, Journal of Cancer Research and Clinical Oncology.

[6]  G. O’Keeffe,et al.  Romidepsin induces caspase-dependent cell death in human neuroblastoma cells , 2017, Neuroscience Letters.

[7]  J. Trent,et al.  The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type , 2017, The Journal of pathology.

[8]  A. Arya,et al.  Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas , 2017, Scientific Reports.

[9]  Shanchun Guo,et al.  Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells , 2017, Oncotarget.

[10]  B. Yan,et al.  Histone deacetylase 1 activates PU.1 gene transcription through regulating TAF9 deacetylation and transcription factor IID assembly , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  K. Mills,et al.  Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy , 2017, Oncotarget.

[12]  P. Richardson,et al.  KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival , 2017, Leukemia.

[13]  Zhiwei Wang,et al.  Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells , 2017, OncoTargets and therapy.

[14]  R. C. Poulos,et al.  The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription. , 2017, Cancer research.

[15]  F. Martinon,et al.  Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. , 2017, Blood.

[16]  M. Pistillo,et al.  Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells , 2017, Oncotarget.

[17]  J. Carroll,et al.  ERRα induces H3K9 demethylation by LSD1 to promote cell invasion , 2017, Proceedings of the National Academy of Sciences.

[18]  Peng Zhang,et al.  Snail acetylation by histone acetyltransferase p300 in lung cancer , 2017, Thoracic cancer.

[19]  B. Porse,et al.  EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas , 2017, Nature Medicine.

[20]  J. Harrell,et al.  HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth. , 2017, Molecular cancer research : MCR.

[21]  C. Rudin,et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.

[22]  Sukrit Singh,et al.  The small molecule JIB-04 disrupts O2 binding in the Fe-dependent histone demethylase KDM4A/JMJD2A. , 2017, Chemical communications.

[23]  D. Ma,et al.  Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer , 2017, Journal of Hematology & Oncology.

[24]  J. Łuszczki,et al.  Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells , 2017, Journal of Cancer.

[25]  G. Kristiansen,et al.  The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo , 2016, Journal of cellular and molecular medicine.

[26]  Mengzhong Liu,et al.  P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line , 2016, Oncology letters.

[27]  P. Park,et al.  A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.

[28]  P. Qiu,et al.  BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells , 2016, Leukemia.

[29]  Peter A. Jones,et al.  Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine , 2016, Proceedings of the National Academy of Sciences.

[30]  R. Prinjha,et al.  Structural analysis of human KDM5B guides histone demethylase inhibitor development. , 2016, Nature chemical biology.

[31]  J. Harrell,et al.  HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth , 2016, Molecular Cancer Research.

[32]  A. Harris,et al.  The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer , 2016, Oncogene.

[33]  K. Helin,et al.  Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells , 2016, Genes & development.

[34]  Scott A. Armstrong,et al.  MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. , 2016, The Journal of clinical investigation.

[35]  Mariko Sasaki,et al.  Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. , 2016, Cancer discovery.

[36]  B. Radotra,et al.  Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis , 2016, Molecular and Cellular Biochemistry.

[37]  Andrew P. Feinberg,et al.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression , 2016, Nature Reviews Genetics.

[38]  Sheng Han,et al.  Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27 , 2016, Journal of experimental & clinical cancer research : CR.

[39]  A. Mai,et al.  The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. , 2016, Biochemical pharmacology.

[40]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[41]  R. Kruger,et al.  Antitumor activity of LSD1 inhibitors in lung cancer , 2016, Molecular & cellular oncology.

[42]  A. Chiang,et al.  Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib , 2015, Oncotarget.

[43]  R. Dummer,et al.  Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL , 2015, Clinical Cancer Research.

[44]  S. Armstrong,et al.  Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML , 2015, Nature.

[45]  S. Mok,et al.  KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1 , 2015, Oncotarget.

[46]  Francisco J. Sánchez-Rivera,et al.  Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma , 2015, Nature Medicine.

[47]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[48]  M. Beckmann,et al.  Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .

[49]  Wenxin Qin,et al.  KDM6B Elicits Cell Apoptosis by Promoting Nuclear Translocation of FOXO1 in Non-Small Cell Lung Cancer , 2015, Cellular Physiology and Biochemistry.

[50]  A. Abad,et al.  Abstract 5478: Curcumin mediates reversion to oxaliplatin-acquired resistance in colorectal cancer cell lines through modulation of nuclear factor κB (NFκB) and cyclin-dependent kinase 5 (CDK5) , 2015 .

[51]  G. Kong,et al.  DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression , 2015, Nature Communications.

[52]  Qiang Li,et al.  KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG. , 2015, International journal of clinical and experimental pathology.

[53]  Wei-Hwa Lee,et al.  JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells , 2015, PloS one.

[54]  A. Chalk,et al.  BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells , 2015, Scientific Reports.

[55]  T. Chevassut,et al.  DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. , 2014, Blood.

[56]  H. Deeg,et al.  Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors , 2014 .

[57]  Junjiang Fu,et al.  MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. , 2014, Cancer letters.

[58]  M. Fukayama,et al.  Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. , 2014, Carcinogenesis.

[59]  C. Wahlestedt,et al.  The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers* , 2014, The Journal of Biological Chemistry.

[60]  Liping Wei,et al.  Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer , 2014, Oncotarget.

[61]  Zhoulei Li,et al.  BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma , 2014, Proceedings of the National Academy of Sciences.

[62]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[63]  David T. W. Jones,et al.  Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing , 2014, Nature.

[64]  G. Kristiansen,et al.  Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer , 2014, BMC Clinical Pathology.

[65]  Tim J. Wigle,et al.  Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.

[66]  B. Coiffier,et al.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses , 2014, Journal of Hematology & Oncology.

[67]  H. Okinaga,et al.  Histone acetyltransferase Hbo1 destabilizes estrogen receptor α by ubiquitination and modulates proliferation of breast cancers , 2013, Cancer science.

[68]  S. Fox,et al.  Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes , 2013, PloS one.

[69]  S. Peña-Llopis,et al.  A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth , 2013, Nature Communications.

[70]  W. Weichert,et al.  Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression , 2013, BMC Cancer.

[71]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[72]  A. Mobasheri,et al.  Curcumin Enhances the Effect of Chemotherapy against Colorectal Cancer Cells by Inhibition of NF-κB and Src Protein Kinase Signaling Pathways , 2013, PloS one.

[73]  Li-li Wang,et al.  A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells , 2013, PloS one.

[74]  T. Veenstra,et al.  Histone Demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Protein Nuclear Stabilization , 2012, PloS one.

[75]  Cun-Yu Wang,et al.  Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition* , 2012, The Journal of Biological Chemistry.

[76]  M. Beckmann,et al.  Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets , 2012, Oncotarget.

[77]  J. Eberle,et al.  Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. , 2012, The Journal of investigative dermatology.

[78]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[79]  H. Kim,et al.  DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity , 2012, Radiation oncology.

[80]  A. Oyelere,et al.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. , 2012, Journal of medicinal chemistry.

[81]  Prateek Sharma,et al.  Curcumin Induces Cell Death in Esophageal Cancer Cells through Modulating Notch Signaling , 2012, PloS one.

[82]  Brian J. Stevenson,et al.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. , 2012, Genome research.

[83]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[84]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[85]  Chris T. Harvey,et al.  HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia* , 2011, The Journal of Biological Chemistry.

[86]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[87]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[88]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[89]  M. Brattain,et al.  Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor β (TGFβ) Receptor II Leading to Cancer Cell Death* , 2011, The Journal of Biological Chemistry.

[90]  Jennifer A. Smith,et al.  The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3 , 2011, Molecular and Cellular Biology.

[91]  Timothy J. Durham,et al.  "Systematic" , 1966, Comput. J..

[92]  Andrew J. Bannister,et al.  Regulation of chromatin by histone modifications , 2011, Cell Research.

[93]  Timothy J. Durham,et al.  Systematic analysis of chromatin state dynamics in nine human cell types , 2011, Nature.

[94]  G. Bar-Sela,et al.  Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer , 2010, Nutrition and cancer.

[95]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[97]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[98]  P. Atadja,et al.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma , 2010, Haematologica.

[99]  B. Ponder,et al.  Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway , 2010, Molecular Cancer.

[100]  M. Mouret-Reynier,et al.  Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer , 2010, Cancer biology & therapy.

[101]  Yi Tang,et al.  Acetylation Is Indispensable for p53 Activation , 2008, Cell.

[102]  M. Jeffers,et al.  Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer , 2008, International journal of cancer.

[103]  E. Seto,et al.  Histone deacetylases and cancer , 2007, Oncogene.

[104]  C. Tzao,et al.  Epigenetic Inactivation of the Chromosomal Stability Control Genes BRCA1, BRCA2, and XRCC5 in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[105]  J. Issa,et al.  DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. , 2006, Cancer research.

[106]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[107]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[108]  M. Duvic,et al.  Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2005, The Journal of investigative dermatology.

[109]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[110]  Udaykumar Ranga,et al.  Curcumin, a Novel p300/CREB-binding Protein-specific Inhibitor of Acetyltransferase, Represses the Acetylation of Histone/Nonhistone Proteins and Histone Acetyltransferase-dependent Chromatin Transcription* , 2004, Journal of Biological Chemistry.

[111]  S. Bates,et al.  T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. , 2004, Blood.

[112]  E. Rosen,et al.  Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth , 2003, Molecular and Cellular Biology.

[113]  J. Kutok,et al.  MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. , 2003, Cancer cell.

[114]  Peter A. Jones,et al.  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.

[115]  Hirokazu Nagai,et al.  Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. , 2002, Blood.

[116]  Kevin Struhl,et al.  Methylation of H3-Lysine 79 Is Mediated by a New Family of HMTases without a SET Domain , 2002, Current Biology.

[117]  B. Aggarwal,et al.  Activation of Transcription Factor NF-κB Is Suppressed by Curcumin (Diferuloylmethane) (*) , 1995, The Journal of Biological Chemistry.

[118]  Wenqi Shan,et al.  HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. , 2017, American journal of cancer research.

[119]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[120]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.